Surprising news. I mean, what else was there to do other than try to work with Denner to sell the company in the next 12 months and make a boat load on your "hopefully" appreciated options. Strange....
Well at least Tom Reilly, the CFO, seems to be sticking around since he signed the SEC filing. It certainly sounded like KM was trying to convince Denner with his public comments during the last earnings call that Amarin is on the right track and should plunge ahead as it had already planned.
Have to wonder if countries that are in negotiations with Amarin on pricing and for approval of Vascepa will put the brakes on their talks until they see who they are dealing with in what essentially now is a company with new ownership.
I would hope the Denner folks put out some kind of statement later today to try to calm the waters.